The stock price performance over the year has been a mixed bag, resulting in a range of outlooks from optimistic to pessimistic depending on the observer. Until today this year the stock’s price performance recorded a decrease of -13.62%. However, over the last six months, the performance has been stronger by -38.26%. The price of ALLO decreased -15.21% over the last 30 days. And in the last five days, it has fallen by -4.17%.
Allogene Therapeutics Inc saw a rather unpredictable run in, in terms of market performance. The company’s stock reached its highest point at $5.78 on 03/08/24, while the lowest price for the same duration was marked at $1.78 on 01/21/25.
52-week price history of ALLO Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Allogene Therapeutics Inc’s current trading price is -68.14% away from its 52-week high, while its distance from the 52-week low is 3.37%. The stock’s price range during this period has varied between$1.78 and $5.78. The Allogene Therapeutics Inc’s shares, which operate in the Healthcare, saw a trading volume of around 1.8 million for the day, a figure considerably lower than their average daily volume of 2.72 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Allogene Therapeutics Inc (ALLO) has experienced a quarterly decline of -24.59% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 385.80M and boasts a workforce of 233 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 2.4316, with a change in price of -0.7400. Similarly, Allogene Therapeutics Inc recorded 2,402,199 in trading volume during the last 100 days, posting a change of -28.68%.
ALLO’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for ALLO stands at 0.20. Similarly, the long-term debt-to-equity ratio is also 0.18.
ALLO Stock Stochastic Average
Allogene Therapeutics Inc’s raw stochastic average for the past 50 days is presently 6.06%, as of today. This marks a decrease from the raw stochastic average of the last 20 days, which was 9.60%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 19.20% and 21.87%, respectively.
